James Mond is EVP & CSO and CMO at ADMA BIOLOGICS, INC. (ADMA). They have made 8 open-market trades across 1 company since 2014, most recently 2021-02-25.
CIK 0001554537
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $108K since 2014, never a sale. Across 8 scored buys the stock is down 5.3% at ninety days, and 7.0 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ADMA | 137,535 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2021-03-01 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 13% | 25% | 25% |
| Avg Move | -6.3% | -9.3% | -5.3% |
| Alpha | -4.1% | -8.2% | -7.0% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMA | BUY | 2020-09-08 | 2020-09-10 | $2.20 | $9K | -3.9% | +4.3% | -4.3% |
| ADMA | BUY | 2020-08-10 | 2020-08-12 | $2.88 | $20K | -1.0% | -22.8% | -37.2% |
| ADMA | BUY | 2020-02-11 | 2020-02-11 | $3.50 | $15K | -7.9% | -42.4% | -29.7% |
| ADMA | BUY | 2019-05-17 | 2019-05-21 | $4.00 | $18K | -5.6% | -18.0% | -7.9% |
| ADMA | BUY | 2017-11-09 | 2017-11-13 | $2.15 | $22K | +12.7% | -10.6% | +35.3% |
| ADMA | BUY | 2016-05-03 | 2016-05-05 | $6.50 | $5K | -4.1% | +18.3% | +4.3% |
| ADMA | BUY | 2015-03-16 | 2015-03-18 | $8.02 | $10K | -20.4% | -1.5% | -1.5% |
| ADMA | BUY | 2014-05-14 | 2014-05-16 | $7.60 | $10K | -20.4% | -1.5% | -1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.